CureMetrix and Applied Radiology to Feature Roundtable on AI Innovations in Mammography for Breast Cancer Awareness Month
CureMetrix and Applied Radiology are joining forces to communicate the value (clinical, operational, and financial) of implementing AI-based mammography solutions and their impact on women’s health outcomes days before Breast Cancer Awareness Month. The roundtable, “Extending the Value of Mammography from Breast Health to Women’s Health,” will be held Tuesday, September 28, 2021 from 1:00 to 2:00 pm US-EDT. Registration is open for the event.
An esteemed group of radiologists and cardiologists will review AI tools for breast cancer screening, and share their perspectives on innovative AI decision support tools designed to stratify coronary heart disease (CHD) risk by detecting and quantifying breast arterial calcifications (BAC) from screening mammograms. They will also explore the potential impact these applications can have on global population health outcomes by identifying women at risk of a coronary event.
“This session will shed light on the incredible value that AI brings to mammography in supporting overall women’s health,” said Navid Alipour, CEO of CureMetrix. “By utilizing the routine nature of screening mammograms combined with the power of AI, women can be assessed in the same visit for more than just breast cancer. Leveraging a woman’s regular breast cancer screening to now include heart disease detection creates value in the healthcare system for patients and radiologists – bringing more importance to this year’s campaign on Breast Cancer Awareness and its impact on women’s health.”
AI for breast cancer represents 12% of the total applications of AI in Radiology. Deep learning algorithms in mammography are on the rise for triage, detection, tissue density and risk assessment. Meanwhile, there’s mounting evidence suggesting AI may have a broader impact by helping radiologists provide heart health assessments from mammograms. New AI decision support tools being developed by CureMetrix extend the utility of screening mammography beyond breast cancer by detecting, quantifying, scoring, and auto-reporting clinically significant levels of Breast Arterial Calcification – a surrogate marker for Coronary Artery Calcification (CAC).